Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, sold 3,000 shares of the company's common stock on April 15, 2026. The shares were disposed of at $140.96 apiece, producing gross proceeds of $422,880. Following the trade, Dickinson's direct ownership stands at 176,191 shares.
The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan that Dickinson adopted on August 29, 2024. At the time of the transaction, Gilead's shares were trading around $138.49. Over the prior 12 months the stock delivered a 36% total return. The company carries a reported market capitalization of $172 billion.
Beyond the insider transaction, Gilead has announced several business developments. The company said it is expanding access to lenacapavir, its HIV prevention drug, with the goal of reaching an additional 1 million people. That expansion would bring the cumulative target to 3 million people by 2028 in high-incidence, resource-limited countries. The initiative is supported by investments from the U.S. State Department, PEPFAR, and The Global Fund.
Gilead also disclosed an expanded multi-year collaboration with Tempus AI aimed at accelerating its oncology pipeline. Under the arrangement, Gilead will gain access to Tempus' Lens platform along with comprehensive datasets and analytical services to support oncology research and development.
On the analyst front, Truist Securities raised its price target for Gilead to $155 and reaffirmed a Buy rating, citing expectations for relatively steady financial performance and projecting first-quarter 2026 revenue to be roughly in line with consensus. In contrast, RBC Capital reiterated a Sector Perform rating and a $123 price target after reviewing early prescription trends for Yeztugo during its initial launch phase.
These recent moves - an insider sale under a 10b5-1 plan, stepped-up access initiatives for an HIV prevention product, a technology partnership focused on oncology, and mixed analyst assessments - compose the latest public signals from Gilead. The company continues to pursue product expansion and research collaborations while subject to evolving prescription trends and analyst scrutiny.
Contextual note - The transaction described was carried out via a previously established Rule 10b5-1 plan. No further motive or intent for the sale is stated in the public disclosure beyond that procedural detail.